SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
IDEXX Laboratories, Inc. (IDXX) trades at a trailing P/E of 44.1, forward P/E of 40.2. Trailing earnings yield is 2.27%, forward earnings yield 2.49%. PEG 1.95. Graham Number is $77.23.
Criteria proven by this page:
- VALUE (31/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 44.1).
- Forward P/E 40.2 (down from trailing 44.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.95 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 2.27% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 2.49% as earnings recover.
- Analyst consensus target $784.38 (+34.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 71/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
31/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IDXX
Valuation Multiples
P/E (TTM)44.1
Forward P/E40.2
PEG Ratio1.95
Forward PEG3.66
P/B Ratio29.11
P/S Ratio10.79
EV/EBITDA31.4
Per Share Data
EPS (TTM)$13.23
Forward EPS (Est.)$14.52
Book Value / Share$20.04
Revenue / Share$53.73
FCF / Share$13.15
Yields & Fair Value
Earnings Yield2.27%
Forward Earnings Yield2.49%
Dividend Yield0.00%
Graham Number$77.23
SharesGrow IV$394.53 (-32.4%)
Analyst Target$784.38 (+34.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
47.4 |
2.45 |
-97.12 |
5.93 |
- |
| 2017 |
52.2 |
2.43 |
-253.67 |
6.97 |
- |
| 2018 |
42.9 |
0.96 |
-1,698.56 |
7.30 |
- |
| 2019 |
52.6 |
3.62 |
126.71 |
9.34 |
- |
| 2020 |
73.3 |
1.97 |
67.49 |
15.76 |
- |
| 2021 |
75.3 |
2.68 |
81.31 |
17.45 |
- |
| 2022 |
50.2 |
-7.08 |
56.04 |
10.13 |
- |
| 2023 |
54.6 |
2.16 |
31.06 |
12.59 |
- |
| 2024 |
38.4 |
6.51 |
21.37 |
8.75 |
- |
| 2025 |
51.1 |
2.30 |
33.75 |
12.59 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.44 |
$1.78B |
$222.05M |
12.5% |
| 2017 |
$2.94 |
$1.97B |
$263.14M |
13.4% |
| 2018 |
$4.26 |
$2.21B |
$377.03M |
17% |
| 2019 |
$4.89 |
$2.41B |
$427.72M |
17.8% |
| 2020 |
$6.71 |
$2.71B |
$581.78M |
21.5% |
| 2021 |
$8.60 |
$3.22B |
$744.85M |
23.2% |
| 2022 |
$8.03 |
$3.37B |
$679.09M |
20.2% |
| 2023 |
$10.06 |
$3.66B |
$845.04M |
23.1% |
| 2024 |
$10.67 |
$3.9B |
$887.87M |
22.8% |
| 2025 |
$13.08 |
$4.3B |
$1.06B |
24.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$14.56 |
$14.40 – $14.74 |
$4.68B |
$4.67B – $4.71B |
11 |
| 2027 |
$16.45 |
$15.95 – $16.95 |
$5.09B |
$5.05B – $5.15B |
10 |
| 2028 |
$18.75 |
$17.56 – $19.89 |
$5.58B |
$5.58B – $5.58B |
8 |
| 2029 |
$21.46 |
$21.24 – $21.74 |
$6.16B |
$6.11B – $6.23B |
6 |
| 2030 |
$26.21 |
$25.95 – $26.56 |
$7B |
$6.94B – $7.07B |
6 |
